Urine detection of Histoplasma antigens among symptomatic people living with HIV (PLWH) in Mato Grosso do Sul, Brazil: A comparative study of EIA and lateral flow assay.
Danielle G da Silva, Pedro A L Lemke, Randolph E S Paredes, Arthur P Dos Santos, Barbara C Amorim, Thaynara Azevedo Dos Santos, Leilane Souza do Prado Tair, Vinícius Lopes Teodoro Felix, Taynara Nogueira Martins, Nathalia Antunes Maciel, Wesllaine Milanezi Rosa, Diego H Cáceres, Alexandre A Bertucci, Fernanda Paes Reis, Wellington S Fava, Marcia de C S Melhem, Rinaldo P Mendes, Anamaria M M Paniago, James Venturini
{"title":"Urine detection of Histoplasma antigens among symptomatic people living with HIV (PLWH) in Mato Grosso do Sul, Brazil: A comparative study of EIA and lateral flow assay.","authors":"Danielle G da Silva, Pedro A L Lemke, Randolph E S Paredes, Arthur P Dos Santos, Barbara C Amorim, Thaynara Azevedo Dos Santos, Leilane Souza do Prado Tair, Vinícius Lopes Teodoro Felix, Taynara Nogueira Martins, Nathalia Antunes Maciel, Wesllaine Milanezi Rosa, Diego H Cáceres, Alexandre A Bertucci, Fernanda Paes Reis, Wellington S Fava, Marcia de C S Melhem, Rinaldo P Mendes, Anamaria M M Paniago, James Venturini","doi":"10.1093/mmy/myag088","DOIUrl":null,"url":null,"abstract":"<p><p>Histoplasma spp., thermally dimorphic fungus acquired from environmental exposure, is associated with high mortality in people with advanced HIV disease. Early diagnosis remains challenging because conventional mycological methods have limited sensitivity, reinforcing the importance of urinary antigen detection. We conducted a cross-sectional study between 2022 and 2023 at a tertiary referral hospital in Campo Grande, Mato Grosso do Sul, Brazil, to assess the agreement between two urinary Histoplasma antigen detection platforms and to evaluate Histoplasma antigenuria among symptomatic people living with HIV (PLWH) with suspected disseminated histoplasmosis (DH). During the study period, 241 PLWH underwent urinary Histoplasma antigen testing with both an enzyme immunoassay (EIA; IMMY Clarus® Histoplasma Galactomannan Antigen) and a lateral flow assay (LFA; MiraVista Histoplasma LFA) at our laboratory. Of these, 78 fulfilled the predefined clinical eligibility criteria for suspected DH and were included in the study. Additional immunodiagnostic assays for paracoccidioidomycosis, aspergillosis, and cryptococcosis were also performed. Urinary Histoplasma antigen was detected in 18 patients, corresponding to a frequency of 23.1% (95% confidence interval [CI], 14.6%-34.2%) among symptomatic PLWH with suspected DH. The most frequent clinical manifestations were weight loss (84.6%), fever (80.8%), and cough (71.8%). Coinfections were common, and the case fatality rate among antigen-positive patients was 27.8% (5/18; 95% CI, 10.7-53.6). Inter-assay agreement between EIA and LFA was high (93.6%). Our findings demonstrate a substantial frequency of urinary Histoplasma antigen positivity in this selected cohort of symptomatic PLWH with suspected DH and support further evaluation of antigen-based diagnostic strategies in similar tertiary-care settings.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myag088","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Histoplasma spp., thermally dimorphic fungus acquired from environmental exposure, is associated with high mortality in people with advanced HIV disease. Early diagnosis remains challenging because conventional mycological methods have limited sensitivity, reinforcing the importance of urinary antigen detection. We conducted a cross-sectional study between 2022 and 2023 at a tertiary referral hospital in Campo Grande, Mato Grosso do Sul, Brazil, to assess the agreement between two urinary Histoplasma antigen detection platforms and to evaluate Histoplasma antigenuria among symptomatic people living with HIV (PLWH) with suspected disseminated histoplasmosis (DH). During the study period, 241 PLWH underwent urinary Histoplasma antigen testing with both an enzyme immunoassay (EIA; IMMY Clarus® Histoplasma Galactomannan Antigen) and a lateral flow assay (LFA; MiraVista Histoplasma LFA) at our laboratory. Of these, 78 fulfilled the predefined clinical eligibility criteria for suspected DH and were included in the study. Additional immunodiagnostic assays for paracoccidioidomycosis, aspergillosis, and cryptococcosis were also performed. Urinary Histoplasma antigen was detected in 18 patients, corresponding to a frequency of 23.1% (95% confidence interval [CI], 14.6%-34.2%) among symptomatic PLWH with suspected DH. The most frequent clinical manifestations were weight loss (84.6%), fever (80.8%), and cough (71.8%). Coinfections were common, and the case fatality rate among antigen-positive patients was 27.8% (5/18; 95% CI, 10.7-53.6). Inter-assay agreement between EIA and LFA was high (93.6%). Our findings demonstrate a substantial frequency of urinary Histoplasma antigen positivity in this selected cohort of symptomatic PLWH with suspected DH and support further evaluation of antigen-based diagnostic strategies in similar tertiary-care settings.
期刊介绍:
Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.